HDAC11 and breast carcinoma: HDAC11 is overexpressed in certain cancer cell lines, including prostatic (PC-3) (Huo et al., 2020), ovarian (SK-OV-3) (Zhou et al., 2018), and breast cancer (MCF-7) (Gao et al., 2002) cells, and HDAC11 inhibition has shown beneficial effects in neuroblastoma cells (Thole et al., 2017) and Hodgkin lymphoma (Buglio et al., 2011).